Beranda › Kanker Paru › Connecticut › Hartford
Uji klinis Kanker Paru di Hartford, CT
11 studi untuk Kanker Paru mencari peserta di lokasi sekitar Hartford (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Menerima pesertaFase 3
- Hartford Hospital, Hartford
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury · 5 mi jauhnya
- dan 1 lainnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Hartford Hospital, Hartford
- Hartford HealthCare - Avon, Avon · 8 mi jauhnya
- Hartford HealthCare - Manchester, Manchester · 8 mi jauhnya
- dan 1 lainnya
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Hartford Hospital, Hartford
Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester · 8 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury · 5 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury · 5 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury · 5 mi jauhnya
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Menerima pesertaFase 1/2
- Hartford Hospital (site 210), Hartford
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Hartford
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Menerima pesertaStudi observasional
- Trinity Health Of New England, Hartford
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Hartford
- Kanker Paru Non-Sel Kecil12 studi
- Gangguan Depresi Mayor9 studi
- Kanker (semua jenis)9 studi
- Kanker Payudara9 studi
- Neuroblastoma8 studi
- Mieloma Multipel7 studi
- Kanker Pankreas7 studi
- Kanker Prostat7 studi
- Kanker Ovarium7 studi
- Penyakit Kardiovaskular7 studi
- Gagal Jantung7 studi
- Penyakit Sel Sabit5 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.